Sensei biotherapeutics reports first quarter 2024 financial results and recent business highlights

- completed sns-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - company to present topline clinical data from the sns-101 phase 1 dose escalation study at the 2024 asco annual meeting - - enrollment in the dose expansion portion of the clinical study advancing - - strong balance sheet with cash runway into fourth quarter of 2025 - boston, may 09, 2024 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended march 31, 2024, and provided corporate updates. “building upon our initial data for sns-101, which we believe support a favorable and potentially best-in-class clinical safety and pk profile, we now look forward to sharing topline dose escalation data at asco in june and initial dose expansion data in the fourth quarter of this year,” said john celebi, president and chief executive officer.
SNSE Ratings Summary
SNSE Quant Ranking